Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

World Medical Association Declaration of Helsinki

JAMA · 2013 · 29.4K citations

Health Professions, Health Sciences, Clinical Medicine +2

UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1

&NA; · Infectious Diseases in Clinical Practice · 2001 · 1.7K citations

Life Sciences, Genetics, Molecular Genetics +17

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS

David R. Bangsberg, Sharon Perry, Edwin D. Charlebois et al. · AIDS · 2001 · 968 citations

Public Health, Health Sciences, Disease Surveillance +15

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases · 2019 · 750 citations · Full text

Public Health, Pharmacotherapy, Clinical Epidemiology +15

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17